Prosight Management’s Horizon Therapeutics HZNP Stock Holding History
Bought
Maintained
Sold
Other funds holding HZNP
Prosight Management's HZNP Position: Q2 2023 in Review
Prosight Management sold out of Horizon Therapeutics (HZNP) in Q2 2023, closing a stake of 81,035 shares — an estimated $8.84M sold.
Prosight Management first reported a position in HZNP in Q3 2022 and held it in 3 quarters. The position peaked at $18.8M in Q3 2022. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.
- Prosight Management reported no remaining Horizon Therapeutics position as of Q2 2023 after selling out during the quarter.
- Prosight Management sold 81,035 Horizon Therapeutics shares in Q2 2023, an estimated $8.84M.
- Prosight Management first reported a position in Horizon Therapeutics in Q3 2022 and held it in 3 quarters.
- Prosight Management's Horizon Therapeutics position peaked at $18.8M in Q3 2022.
- 517 funds tracked by Wall St. Rank held Horizon Therapeutics as of Q2 2023.
Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.